A Multi-Center, Open-Label, Single-Arm Phase II/III Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 to >65 Years with Newly-Diagnosed Philadelphia-Negative ALL
Details
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.
Eligibility
You can join if...
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
Inclusion Requirements
If you are ≥22 and <55 years old with B-Cell or T-Cell ALL
Exclusion Requirements
You cannot participate in this study if you are female who is pregnant or breastfeeding or planning to become pregnant.